Wells Fargo’s Regeneron Pharmaceuticals REGN Stock Holding History

Wells Fargo’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$96.2K	–	7361
2024 Q1	$96.2K	Hold	100	–	–	﹤0.01%	4919
2023 Q4	$87.8K	Hold	100	–	–	﹤0.01%	4983
2023 Q3	$82.3K	Hold	100	–	–	﹤0.01%	4900
2023 Q2	$71.9K	Hold	100	–	–	﹤0.01%	5229
2023 Q1	$82.2K	Buy	+100	New	+$75.4K	﹤0.01%	4907
2022 Q4	–	Sell	-9,100	Closed	-$6.27M	–	7675
2022 Q3	$6.27M	Buy	+9,100	New	+$5.73M	﹤0.01%	1838
2017 Q1	–	Sell	-6,000	Closed	-$57K	–	6463
2016 Q4	$57K	Hold	6,000	–	–	﹤0.01%	5345
2016 Q3	$90K	Hold	6,000	–	–	﹤0.01%	4978
2016 Q2	$270K	Buy	+6,000	New	+$2.31M	﹤0.01%	4243

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wells Fargo's REGN Position: Q1 2026 in Review

Wells Fargo increased its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, buying an estimated $1.51M and bringing the position to 142,021 shares worth $110M. The position accounts for 0.02% of the portfolio, ranked #597.

Wells Fargo first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $580M in Q2 2015. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Wells Fargo held 142,021 shares of Regeneron Pharmaceuticals worth $110M as of Q1 2026.
Wells Fargo bought 1,972 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.51M.
Regeneron Pharmaceuticals made up 0.02% of Wells Fargo's portfolio in Q1 2026, its #597 holding.
Wells Fargo first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's Regeneron Pharmaceuticals position peaked at $580M in Q2 2015.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.